- Home
- ASM vs CDNA Comparison
ASM vs CDNA Comparison
Compare ASM & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- CDNA
- Stock Information
- Founded
- ASM 1968
- CDNA 1998
- Country
- ASM Canada
- CDNA United States
- Employees
- ASM N/A
- CDNA N/A
- Industry
- ASM Metal Mining
- CDNA Medical Specialities
- Sector
- ASM Basic Materials
- CDNA Health Care
- Exchange
- ASM Nasdaq
- CDNA Nasdaq
- Market Cap
- ASM 798.8M
- CDNA 712.2M
- IPO Year
- ASM N/A
- CDNA 2014
- Fundamental
- Price
- ASM $5.51
- CDNA $17.69
- Analyst Decision
- ASM Strong Buy
- CDNA Buy
- Analyst Count
- ASM 3
- CDNA 7
- Target Price
- ASM $5.27
- CDNA $26.00
- AVG Volume (30 Days)
- ASM 4.0M
- CDNA 1.2M
- Earning Date
- ASM 11-06-2025
- CDNA 11-04-2025
- Dividend Yield
- ASM N/A
- CDNA N/A
- EPS Growth
- ASM 476.57
- CDNA N/A
- EPS
- ASM 0.14
- CDNA 1.22
- Revenue
- ASM $86,065,000.00
- CDNA $357,998,000.00
- Revenue This Year
- ASM $37.72
- CDNA $12.73
- Revenue Next Year
- ASM $26.15
- CDNA $11.90
- P/E Ratio
- ASM $37.46
- CDNA $14.66
- Revenue Growth
- ASM 58.42
- CDNA 14.46
- 52 Week Low
- ASM $0.85
- CDNA $10.96
- 52 Week High
- ASM $6.67
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- ASM 63.80
- CDNA 63.46
- Support Level
- ASM $4.12
- CDNA $17.50
- Resistance Level
- ASM $4.83
- CDNA $18.25
- Average True Range (ATR)
- ASM 0.34
- CDNA 0.76
- MACD
- ASM 0.10
- CDNA 0.18
- Stochastic Oscillator
- ASM 95.61
- CDNA 80.65
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.